According to @CNBC, Eli Lilly's next-generation obesity drug retatrutide delivered strong weight loss and reduced knee pain in a late-stage trial. Source: CNBC. The report highlights efficacy signals for retatrutide in a late-stage setting, indicating notable clinical progress within Eli Lilly's obesity pipeline. Source: CNBC. The post did not provide details on LLY share price reaction, regulatory timelines, or implications for BTC, ETH, or broader crypto markets. Source: CNBC.